Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).

2025-525076-29-00 Protocol PETRA-MBF2 Human pharmacology (Phase I) - Other Ended

Start 23 Mar 2026 · End 6 May 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol PETRA-MBF2

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 6
Countries 1
Sites 1

Phase I study in healthy male volunteers. Intended indication: prophylaxis of transplant rejection in liver, kidney or heart allograft recipients and for treatment of allograft rejection

Key facts

Sponsor
Nucleus Medical GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Phenomena and Processes [G] - Immune system processes [G12]
Trial duration
23 Mar 2026 → 6 May 2026
Decision date (initial)
2026-03-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Phase I study in healthy male volunteers. Intended indication: prophylaxis of transplant rejection in liver, kidney or heart allograft recipients and for treatment of allograft rejection

VersionLevelCodeTermSystem organ class
21.1 PT 10048870 Prophylaxis against transplant rejection 100000004865
20.0 PT 10023439 Kidney transplant rejection 100000004870
21.1 LLT 10050434 Prophylaxis against liver transplant rejection 10042613
21.1 LLT 10050432 Prophylaxis against heart transplant rejection 10042613

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Nucleus Medical GmbH

Sponsor organisation
Nucleus Medical GmbH
Address
Bavariafilmplatz 7, Geiselgasteig Geiselgasteig
City
Gruenwald
Postcode
82031
Country
Germany

Scientific contact point

Organisation
Nucleus Medical GmbH
Contact name
Elke Hortskotte

Public contact point

Organisation
Nucleus Medical GmbH
Contact name
Wolfgang Beier

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 6 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
Nuvisan GmbH
Clinical Services, Wegenerstrasse 13, Ludwigsfeld, Neu-Ulm

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2026-03-23 2026-05-06 2026-03-23 2026-03-31

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-01-16 Germany Acceptable
2026-02-18
2026-03-04